A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer (NCT05710848)
A Phase 1/2a Study of STM-416 Administered Intraoperatively to Patients Undergoing Transurethral Resection of Bladder Tumor (TURBT) for Recurrent High-Grade Papillary Bladder Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
Who can join: Review the eligibility criteria below.
Location: East Valley Urology Center of Arizona — Mesa, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- East Valley Urology Center of Arizona — Mesa, Arizona
- Arizona Urology Specialists — Tucson, Arizona
- Arkansas Urology — Little Rock, Arkansas
- Unio Specialty Care - A Genesis Healthcare Partners Facility — Bakersfield, California
- Genesis Research — Downey, California
- Urology Center of Southern California — Murrieta, California
- Advanced Urology Institute — Daytona Beach, Florida
- University of Florida — Gainesville, Florida
- Advent Health — Orlando, Florida
- Anna Arundel Urology — Annapolis, Maryland
- Brigham and Women's Hospital — Boston, Massachusetts
- Michigan Institute of Urology — Troy, Michigan
- The Ohio State University — Columbus, Ohio
- Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Lowcountry Urology — North Charleston, South Carolina
- University of Texas Southwestern Medical Center — Dallas, Texas
- Urology Partners of North Texas — Fort Worth, Texas
- Baylor College of Medicine — Houston, Texas
- Houston Methodist — Houston, Texas
- University of Texas Health Science Center at San Antonio — San Antonio, Texas
📞 Contact the Study Coordinator
Phone: (781) 605-8632
Email: kayti@surgetx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-muscle-invasive Bladder Cancer
- Intravesical BCG vs GEMDOCE in NMIBC — Birmingham, Alabama
- Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer — Auchenflower,
- A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer — Little Rock, Arkansas
- Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance — West Haven, Connecticut
- Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC) — Dallas, Texas
- A Phase I Intravesical PPM Therapy for NMIBC — Boston, Massachusetts
Explore by condition: All Non-muscle-invasive Bladder Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.